| Literature DB >> 29691654 |
Anouk M M Vaes1,2, Elske M Brouwer-Brolsma3, Nicole Toussaint3, Margot de Regt3, Michael Tieland3,4, Luc J C van Loon4,5, Lisette C P G M de Groot3,4.
Abstract
PURPOSE: Sufficient 25-hydroxyvitamin D (25(OH)D) concentrations might prevent a decline in physical performance, and are considered important for the prevention of frailty. This study investigates the association of serum 25(OH)D concentration with physical performance and frailty status in Dutch older adults.Entities:
Keywords: 25-Hydroxyvitamin D; Frailty; Muscle strength; Physical performance; Vitamin D
Mesh:
Substances:
Year: 2018 PMID: 29691654 PMCID: PMC6499878 DOI: 10.1007/s00394-018-1634-0
Source DB: PubMed Journal: Eur J Nutr ISSN: 1436-6207 Impact factor: 5.614
Diagnosis of frailty according to the Fried criteria [1]
| Criterion | Measured method | Cut-offs by sex and height | |||
|---|---|---|---|---|---|
| Weight loss | Unintentional weight loss | Weight loss ≥ 4.5 kg in prior year | |||
| Grip strength | Handgrip strength | Men | Women | ||
| BMI ≤ 24 | ≤ 29 kg | BMI ≤ 23 | ≤ 17 kg | ||
| BMI 24.1–26 | ≤ 30 kg | BMI 23.1–26 | ≤ 17.3 kg | ||
| BMI 26.1–28 | ≤ 30 kg | BMI 26.1–29 | ≤ 18 kg | ||
| BMI > 28 | ≤ 32 kg | BMI > 29 | ≤ 21 kg | ||
| Physical activity | Short version of the Minnesota Questionnaire | Men | Women | ||
| ≤ 1.6 MJ | ≤ 1.1 MJ | ||||
| Gait speed | Gait speed | Men | Women | ||
| Height ≤ 173 cm ≥ 7 s | Height ≤ 159 cm ≥ 7 s | ||||
| Self-reported exhaustion | CES-D Depression Scale | Participants scored positive if one of the following statements were present for ≥ 3d/wk: (a) I felt that everything I did was an effort; (b) I could not get going | |||
Participant characteristics
| Serum 25-hydroxyvitamin D | |||||
|---|---|---|---|---|---|
| Total | < 50 nmol/L | 50–75 nmol/L | > 75 nmol/L | ||
| Men, | 416 (55) | 217 (64) | 125 (49) | 76 (46) | < 0.01 |
| Age, year | 73.8 ± 6.4 | 74.1 ± 6.6 | 74.0 ± 6.2 | 72.9 ± 5.9 | 0.08 |
| BMI, kg/m2 | 27.1 ± 3.5 | 27.5 ± 3.7 | 27.0 ± 3.3 | 26.2 ± 3.1 | < 0.01 |
| Caucasian, | 736 (98) | 327 (97) | 250 (98) | 159 (98) | 0.49 |
| Independent living, | 723 (96) | 320 (95) | 243 (96) | 160 (99) | 0.10 |
| Non-smokers, | 705 (94) | 311 (92) | 239 (94) | 155 (96) | 0.31 |
| Alcohol consumers, | 598 (79) | 269 (80) | 197 (78) | 132 (82) | 0.61 |
| 25(OH)D, nmol/L | 54 (38–72) | 36 (29–42) | 62 (58–67) | 91 (84–100) | < 0.01 |
| Calcium | 2.24 (0.09) | 2.24 (0.09) | 2.25 (0.10) | 2.24 (0.10) | 0.43 |
| VitD suppl. users, | 88 (12) | 13 (4) | 45 (18) | 30 (19) | < 0.01 |
| Season, | |||||
| Summer–autumn | 259 (34) | 64 (19) | 101 (40) | 94 (58) | < 0.01 |
| Winter–spring | 497 (66) | 276 (81) | 153 (60) | 68 (42) | |
| Number of diseases, | |||||
| 0 | 380 (51) | 159 (47) | 130 (52) | 91 (56) | 0.36 |
| 1–2 | 353 (47) | 167 (50) | 117 (46) | 69 (43) | |
| ≥ 3 | 17 (2) | 10 (3) | 5 (2) | 2 (1) | |
| Physical activity, MJ/weekd | 8.4 (4.5–13.0) | 7.8 (4.5–13.1) | 8.5 (4.3–12.0) | 9.6 (5.4–15.1) | 0.11 |
| TUG, sj,d | 9.8 ± 2.4 | 9.9 ± 2.5 | 9.9 ± 2.3 | 9.1 ± 2.2 | 0.04 |
| Gait, m/se | 1.06 ± 0.20 | 1.05 ± 0.21 | 1.05 ± 0.19 | 1.10 ± 0.20 | 0.03 |
| Knee-extension, Nj | 328 ± 104 | 336 ± 103 | 324 ± 104 | 301 ± 106 | 0.04 |
| HGS, kgf | 28.9 ± 9.5 | 29.4 ± 9.3 | 28.1 ± 9.6 | 28.9 ± 9.7 | 0.23 |
| Frailty, | |||||
| Non-frail | 425 (57) | 183 (55) | 142 (57) | 100 (62) | 0.16 |
| Pre-frail | 289 (39) | 131 (39) | 98 (39) | 60 (37) | |
| Frail | 33 (4) | 20 (6) | 11 (4) | 2 (1) | |
| Positive on frailty | |||||
| Weight loss, | 23 (3) | 14 (4) | 5 (2) | 4 (3) | 0.28 |
| Exhaustion, | 115 (15) | 51 (15) | 41 (16) | 23 (14) | 0.86 |
| Physical activity, | 54 (7) | 26 (8) | 20 (8) | 8 (5) | 0.46 |
| HGS, | 213 (28) | 102 (30) | 76 (30) | 35 (22) | 0.10 |
| Gait, | 49 (7) | 26 (8) | 16 (6) | 7 (4) | 0.34 |
Values presented are mean ± SD or median (25th–75th percentile). Between-group differences explored by one-way ANOVA, Kruskal–Wallis test or Chi-square test
25(OH)D 25-hydroxyvitamin D, BMI Body Mass Index, VitD suppl. users vitamin D supplement users; TUG Timed Up and Go, HGS Hand grip strength, N Newton
a3 missing values
b5 missing values
c6 missing values
d1 missing value
e7 missing values
f4 missing values
g9 missing values
hAssisted living includes: home care or service flat
iWinter–spring: Dec–May, summer–autumn: Jun–Nov
jSubgroup n = 494
Association between serum 25-hydroxyvitamin D status and physical performance
| Serum 25-hydroxyvitamin D |
| |||
|---|---|---|---|---|
| < 50 nmol/L | 50–75 nmol/L | > 75 nmol/L | ||
| Reference group | ||||
| TUG, s | ||||
| Model 1 | 0.85 (0.24; 1.45)** | 0.83 (0.19; 1.47)* | 0 (ref) | 493 |
| Model 2 | 0.77 (0.18; 1.36)* | 0.84 (0.22; 1.47)** | 0 (ref) | 493 |
| Model 3 | 0.73 (0.14; 1.32)* | 0.83 (0.21; 1.45)** | 0 (ref) | 488 |
| Gait, m/s | ||||
| Model 1 | − 0.06 (− 0.10; − 0.02)** | − 0.05 (− 0.09; − 0.01)** | 0 (ref) | 749 |
| Model 2 | − 0.05 (− 0.09; − 0.01)** | − 0.04 (− 0.08; − 0.01)* | 0 (ref) | 749 |
| Model 3 | − 0.04 (− 0.08; − 0.01)* | − 0.04 (− 0.07; − 0.01)* | 0 (ref) | 745 |
| HGS, kg | ||||
| Model 1 | − 0.93 (− 2.25; 0.38) | − 0.71 (− 2.02; 0.61) | 0 (ref) | 752 |
| Model 2 | − 1.06 (− 2.38; 0.26) | − 0.84 (− 2.15; 0.47) | 0 (ref) | 752 |
| Model 3 | − 0.92 (− 2.25; 0.40) | − 0.78 (− 2.10; 0.53) | 0 (ref) | 748 |
| Knee-extension, N | ||||
| Model 1 | 7.74 (− 15.03; 30.50) | 12.23 (− 11.95; 36.42) | 0 (ref) | 494 |
| Model 2 | 7.70 (− 15.10; 30.50) | 13.09 (− 11.11; 37.29) | 0 (ref) | 494 |
| Model 3 | 9.89 (− 12.82; 32.60) | 12.71 (− 11.37; 36.80) | 0 (ref) | 489 |
Analyzed by multiple linear regression
Model 1 adjusted for age, sex and laboratory site, Model 2 adjusted for age, sex, laboratory site, BMI and season, Model 3 adjusted for age, sex, laboratory site, BMI, season, ethnicity, physical activity, alcohol, smoking and number of diseases, TUG Timed Up and Go, HGS Hand grip strength, N Newton
*P < 0.05
**P < 0.01
Prevalence ratios (PR) and 95% CIs for frailty status of participants with serum 25-hydroxyvitamin D concentrations < 50 versus ≥ 50 nmol/L
| Serum 25-hydroxyvitamin D |
| ||
|---|---|---|---|
| < 50 nmol/L | ≥ 50 nmol/L | ||
| PR (95% CI) | Reference group | ||
| Frail vs. non-frail | |||
| Model 1 | 2.24 (1.06; 4.75)* | 1 (ref) | 458 |
| Model 2 | 2.07 (1.02; 4.20)* | 1 (ref) | 458 |
| Model 3 | 2.30 (1.11; 4.76)* | 1 (ref) | 453 |
| Pre-frail vs. non-frail | |||
| Model 1 | 1.10 (0.91; 1.32) | 1 (ref) | 714 |
| Model 2 | 1.08 (0.90; 1.29) | 1 (ref) | 714 |
| Model 3 | 1.06 (0.88; 1.26) | 1 (ref) | 711 |
| Pre-frail or frail vs. non-frail | |||
| Model 1 | 1.14 (0.97; 1.35) | 1 (ref) | 747 |
| Model 2 | 1.13 (0.96; 1.32) | 1 (ref) | 747 |
| Model 3 | 1.10 (0.93; 1.29) | 1 (ref) | 742 |
Analyzed by Cox Proportional Hazards analysis
Model 1 adjusted for age, sex and laboratory site, Model 2 adjusted for age, sex, laboratory site, BMI and season, Model 3 adjusted for age, sex, laboratory site, BMI, season, ethnicity, alcohol, smoking and number of diseases. Models are not corrected for physical activity, as this measure is also included in frailty status
*P < 0.05